|Bid||33.11 x 800|
|Ask||39.27 x 900|
|Day's Range||36.69 - 38.92|
|52 Week Range||25.04 - 44.42|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.33|
A look at the shareholders of Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) can tell us which group is most powerful...
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.